Posted by Michael Wonder on 04 Feb 2026
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer
3 February 2026 - GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for injection) in combination with chemotherapy (carboplatin and paclitaxel) for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy.
This expanded indication of Jemperli is now reimbursed by the Régie de l'assurance maladie du Québec (RAMQ). GSK applauds the Government of Quebec for granting timely access to this expanded, evidence-based treatment option for people living with endometrial cancer.
